Legal status · United States
Is Mifepristone legal in the United States?
Written by Aaron CuhaReviewed Sep 2026
Direct answer
Yes. Mifepristone is an approved medicine in the United States, classified as "FDA-approved, prescription only". Approval covers its labeled indication and it is supplied on prescription, not over the counter. Products labeled "research use only" fall outside that approval and the label does not make human use lawful. On the evidence, no human study is cited on its profile.
Mifepristone in the United States at a glance
| Classification | FDA-approved, prescription only |
|---|---|
| Note | Two separate approvals, for Cushing's syndrome hyperglycaemia and for medical termination of pregnancy. The latter is subject to a restricted distribution programme. No ageing indication. |
| FDA approval status | FDA-approved as Korlym for hyperglycaemia secondary to hypercortisolism in Cushing's syndrome, and as Mifeprex for medical termination of pregnancy. Not approved for any ageing indication. |
| Human studies cited | 0 of 1 citations on the profile |
| Reviewed | Sep 2026 |
Classification and note come from the Mifepristone profile, checked against U.S. Food and Drug Administration (FDA) listings at the reviewed date.
What this means
- 01
FDA has approved Mifepristone for at least one labeled indication, so a pharmaceutical-grade product exists in the United States and is dispensed on prescription.
- 02
Approval is indication-specific. Uses outside the label are a clinical decision for a prescriber, not something the approval itself authorizes.
- 03
Unlicensed online vials, including those labeled "research use only", are not the approved product and are not covered by the approval.
What Mifepristone is
Blocking cortisol signalling was a serious longevity hypothesis, because chronic glucocorticoid exposure damages muscle, bone and brain. The mouse lifespan test found nothing in either sex.
The reason anyone tested this is worth stating, because it is a good hypothesis. Cortisol rises with age, and sustained glucocorticoid exposure causes exactly the changes that define ageing badly: muscle wasting, bone loss, visceral fat accumulation, insulin resistance, hippocampal atrophy and immune suppression.
Mechanism: A competitive antagonist at the glucocorticoid receptor, blocking cortisol's transcriptional effects, and at the progesterone receptor, which is the basis of its obstetric use. At the glucocorticoid receptor it prevents the catabolic signalling that drives muscle proteolysis, hepatic gluconeogenesis and adipose redistribution.
Regulatory history: FDA-approved as Korlym for hyperglycaemia secondary to hypercortisolism in Cushing's syndrome, and as Mifeprex for medical termination of pregnancy. Not approved for any ageing indication.
How FDA treats this kind of product
Approves prescription drugs by indication and polices unapproved products, including peptides sold online. Compounding pharmacies may prepare some compounds under a prescription when the FDA places them on a permitted bulk-substances category.
The classification above is the The Longevity Archive reading of U.S. Food and Drug Administration listings for Mifepristone at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.
Mifepristone in other countries
Frequently asked questions
Is Mifepristone legal in the United States?
Yes. Mifepristone is an approved medicine in the United States, classified as "FDA-approved, prescription only". Approval covers its labeled indication and it is supplied on prescription, not over the counter. Products labeled "research use only" fall outside that approval and the label does not make human use lawful. On the evidence, no human study is cited on its profile. Note: Two separate approvals, for Cushing's syndrome hyperglycaemia and for medical termination of pregnancy. The latter is subject to a restricted distribution programme. No ageing indication.
Can I buy Mifepristone in the United States?
Only with a prescription. Mifepristone is classified as "FDA-approved, prescription only" in the United States, so it is dispensed by pharmacies against a prescription for its approved indication. Buying it from unlicensed online sellers or as a "research chemical" is outside that system and carries no regulatory protection. Note: Two separate approvals, for Cushing's syndrome hyperglycaemia and for medical termination of pregnancy. The latter is subject to a restricted distribution programme. No ageing indication.
Is Mifepristone FDA approved?
Yes. FDA status: FDA-approved as Korlym for hyperglycaemia secondary to hypercortisolism in Cushing's syndrome, and as Mifeprex for medical termination of pregnancy. Not approved for any ageing indication.. Current US classification: "FDA-approved, prescription only". On the evidence, no human study is cited on its profile.
Related compounds in the United States
Full research profile
Mechanism, cited studies, FDA status and the full legal summary for Mifepristone live on its compound profile.
Mifepristone profileThis page is general information about the regulatory status of Mifepristone in the United States, current as of Sep 2026. It is not legal advice, and classifications change; check U.S. Food and Drug Administration directly or consult a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships and does not recommend where to buy anything.